Mizuho Bolsters Price Target By 55% On Axsome

 

• Mizuho Securities assumes coverage of Axsome Therapeutics Inc 
  AXSM+0.97%+ Free Alerts
  , with a Buy rating and a price target of $76, representing a 25% upside from the last close is 55% above the initial price target of $49. 
• The analyst is conservative on revenues relative to consensus over the near- and mid-term. It is also below consensus on the cost/expense side, finding merit in Axsome's disciplined spending approach.
• Mizuho sees modest novelty in AXSM's candidates, and the markets it addresses feature meaningful branded and generic competition.
• The analyst also notes that a potentially significant opportunity exists given large markets (e.g., major depressive disorder and migraine) and limited efficacy seen with current standards of care. 

https://www.benzinga.com/general/biotech/22/09/28781655/mizuho-bolsters-price-target-by-55-on-this-migraine-stock